Compare EOG Resources Inc (EOG) vs Novartis AG (NVS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
EOG Resources Inc vs Novartis AG — how do they compare? EOG Resources Inc trades at $149.37 (market cap $77.90B), while Novartis AG trades at $143.32 (market cap $268.57B). The key difference: Novartis AG is far larger — about 3.4× EOG Resources Inc's market cap, and Novartis AG pays the higher dividend (3.31%). Which is the better fit depends on your goals — on Pluang, investors hold EOG Resources Inc for 59 Days and Novartis AG for 82 Days on average.
| EOG | NVS | |
|---|---|---|
Market Cap | $77.90B | $268.57B |
Volume | 2,930,386 | 1,532,573 |
Sector | Energy | Health |
52-Week High | $153.74 | $168.62 |
52-Week Low | $101.78 | $121.80 |
Typical Hold Time | 59 Days | 82 Days |
Enterprise Value | $81.24B | $309.89B |
Dividend Yield | 2.75% | 3.31% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EOG Resources trades at $149.40, up 3.6% today, with a bullish technical outlook and strong fundamentals. The stock has consistently beaten earnings estimates in recent quarters, with Q2 2026 EPS of $5.07 exceeding expectations. Valuation ratios appear attractive, including a P/E of 11.56 and EV/EBITDA of 5.84. Recent news highlights robust operational execution and disciplined capital allocation, with the company announcing a CFO transition and scheduling its Q3 2026 earnings call for November 6.
The outlook for EOG remains positive, supported by strong profitability metrics, a solid balance sheet, and a unanimous analyst buy/hold consensus with no sell ratings. Key opportunities include projected revenue growth to $26.6B in 2026 and a 5% oil volume growth target. Risks involve exposure to volatile oil prices, as seen in recent price retreats impacting energy stocks, and potential execution challenges amid macroeconomic uncertainty. The stock offers value with a consensus price target of $164.77, implying ~10% upside.
Novartis (NVS) trades at $143.28, up 1.77% on the day, with a neutral technical signal and mixed earnings history. The company reported strong 2025 revenue of $56.67B and a net income margin of 22.5%, supported by a recent $7.8B licensing deal with China's Abogen. However, recent clinical trial setbacks and an ongoing law firm investigation introduce uncertainty.
The outlook is balanced; solid profitability and a consensus price target of $146.00 suggest modest upside, but risks from pipeline failures and heightened M&A scrutiny warrant caution. Investor sentiment is mixed, with analysts predominantly holding a neutral stance amid evolving business developments.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About EOG Resources Inc
EOG Resources is an oil and gas producer with acreage in several U.S. shale plays, including the Permian Basin, the Eagle Ford, and the Bakken. At the end of 2021, it reported net proved reserves of 3.7 billion barrels of oil equivalent. Net production averaged 829 thousand barrels of oil equivalent per day in 2021 at a ratio of 72% oil and natural gas liquids and 28% natural gas.
Read more on EOG →About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →
